Metagenomi reports 2023 EPS ($20.05), consensus ($5.42)

Reports revenue $44.7M, consensus $42.56M. “We continue to execute across all aspects of our business. Throughout 2023, we achieved key therapeutic milestones, including preclinical proof of concept in nonhuman primates for our lead program in Hemophilia A. Additionally, we announced a series of industry firsts on our technology platform, including the demonstration of large, complex gene corrections,” said Brian C. Thomas, Chief Executive Officer of Metagenomi. “Looking ahead, we are planning for additional nonhuman primate data readouts over the course of this year, including 12 month data for our Hemophilia A program, expected in the second half of 2024.”